The Week

TScan Therapeutics (TCRX) fell 48.04% this week to close at $0.3915 on Friday, while the S&P 500 gained 0.09%. The stock underperformed the benchmark by about 48.13 percentage points. It opened Monday around $0.75, slipped to $0.6663 on Tuesday, then saw volume swell to roughly 8.5m shares on Wednesday as price fell to $0.3811. Thursday marked a low of $0.3506 before Friday’s modest bounce back to $0.3915. The weekly range was 55.91%, with average daily volume of about 2.9m shares, around 4.7 times the 60-day median daily volume of about 505k shares.

Key Events

On 2 September, TScan Therapeutics announced a strategic reorganisation to focus on in vivo cell therapy for solid tumours, cutting about 75% of its workforce. The same day, the company confirmed CFO Jason A. Amello and CMO Chrystal Louis had been terminated, with Gavin MacBeath taking on financial officer duties. It also disclosed a failure to satisfy a Nasdaq continued listing rule. On the pipeline side, two in vivo TCR-T candidates moved into clinical studies, while two more advanced to IND-enabling stage, with a Phase I trial planned for Q4 2027. TSC-101 showed 79% relapse-free survival at six months in high-risk post-HCT patients, but the company also paused a cancer trial. The stock’s heaviest losses came on Wednesday as these disclosures hit the tape.

Analyst Ratings

Six institutions cover the stock. Three give it a buy or overweight rating, including two strong buys, while four rate it hold. None rate it underweight or sell. The consensus recommendation is buy, with a consensus target of $4.67, roughly 1,092% above the latest price of $0.3915. Targets range from $1.00 to $7.00, reflecting wide disagreement. Within the biotechnology sector, the stock’s rating rank sits at 252 out of about 507 companies, in the middle of the pack.

The Week Ahead

Watch for any follow-up disclosure on the Nasdaq listing rule issue and further details on the reorganised pipeline. On the macro side, the US NFIB small-business optimism index arrives on 8 September. On 10 September, initial jobless claims, PPI, existing-home sales, wholesale sales and EIA natural gas inventories will be released, all of which can sway risk appetite for small-cap biotech names.

In Short

The week’s story is one of strategic shrinkage: TScan cut resources and pivoted to in vivo cell therapy, accompanied by heavy job cuts, a listing-rule risk and a violent repricing. A consensus buy rating and a target far above spot suggest upside potential, but the wide target range and the new low show the market is repricing execution risk. The next test is whether the company can stabilise its market value and show progress on the reorganisation and pipeline during the rest of 2026.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.